BIOMEDICAN Enters the Astaxanthin Market Through Biosynthesis Platform to Target High-Value Compound and Disrupt the Current Technologies

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances.

Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Astaxanthin market comprises of three primary segments: fish feed, animal feed, and human utilization. Astaxanthin's worth is developing astronomically: its market was worth over $1 billion in 2019 and is projected to be worth $3.3 billion by 2027.


Some of the greatest advances in science are unfolding now inside Amgen. Watch the future of biotechnology as it unfolds and hear stories from the scientists making it happen .


Some of the greatest advances in science are unfolding now inside Amgen. Watch the future of biotechnology as it unfolds and hear stories from the scientists making it happen .

Related News


Novo Holdings Leads US$21M Series A Financing in BIOMILQ

Novo Holdings | October 21, 2021

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estimated that 75%1 of women are unable to exclusively breastfeed for the six months after birth as recommended by the American Academy of Pediatrics and the World Health Organization. Breastfeeding can be difficult due to latching issues, birth complications, discomfort or pain, exhaustion, inadequate milk supply, amongst other reasons. Alternative supplements, such as bovine-based infant formula, can lack the nutritional and bioactive composition found in breast milk. BIOMILQ's technology and solutions can be transformative in the field of infant nutrition, a market with a significant need for innovation. "Our mission is to make a growing and positive impact on health, science and society. We are delighted to support BIOMILQ through its journey pioneering mammary biotechnology. Its products have the potential to disrupt the infant supplemental feeding industry. We aim to use our scientific knowledge, operational expertise and global network to further strengthen the Company's ability to improve lives. Kartik Dharmadhikari, Partner at Novo Groand BIOMILQ Board Director Michelle Egger, Chief Executive Officer and Co Founder of BIOMILQ, added: "We are very pleased to have such experienced investors in our Series A financing. Novo Holdings, as a leading international life science investor, lends significant market experience and technical knowhow to BIOMILQ's mission to nourish healthier infants, empower parents through choice, and contribute to a healthier planet. The investor syndicate was led by Novo Holdings, with participation from Breakthrough Energy Ventures, Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund and Gaingels. About Novo Holdings A/S Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information. About BIOMILQ BIOMILQ's mission is to close the nutritional gap between infant feeding options. In June 2021, BIOMILQ announced its capability of producing a milk product, derived from human mammary cells, that has macronutrient profiles that closely match the expected types and proportions of proteins, complex carbohydrates, fatty acids and other bioactive lipids that are known to be abundantly present in breastmilk. 1 "Breastfeeding Among U.S. Children Born 2011–2018, CDC National Immunization Survey." Centers for Disease Control

Read More


Mission Bio and S2 Genomics to Provide Tumor Sample for Single-cell DNA Analysis

Mission Bio | April 20, 2022

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC), validated the automated nuclei workflow, which she presented at the American Association for Cancer Research (AACR) Annual Meeting last week. Single-cell DNA analysis has revolutionized cancer research, allowing researchers to gain high-resolution insights into tumor heterogeneity, leading to a slew of high-profile papers on disease causes. Solid tumor profiling, on the other hand, presents significant problems, as existing prep procedures sometimes fail to yield enough cells or nuclei to offer relevant data. Mission Bio introduced their Tapestri Solution for Solid Tumor Research last month to address this issue, which includes new pre-designed research panels for breast cancer and glioblastoma multiforme, as well as an upgraded single-cell copy number variation (CNV) bioinformatic analysis tool. S2 Genomics' SingulatorTM 100 technology for automated dissociation of solid tissue into single-cell or nuclei suspensions can now be used in conjunction with Tapestri to achieve scalable, high-yield, efficient, and repeatable tissue processing. We are eager to partner with leading companies to address key challenges to sample prep in solid tumor research, As Dr. Iacobuzio-Donahue's lab demonstrates, the Singulator 100 and Tapestri together are a powerful solution enabling single-cell DNA sequencing at scale, in pancreatic cancer research and across a variety of tissue types." Yan Zhang, Ph.D., CEO of Mission Bio. The Singulator 100 has been an important tool for enabling single-cell sequencing in solid tissue, but cancer researchers have been unable to directly interrogate DNA, Tapestri is the only commercial platform capable of single-cell DNA analysis, and we're excited to offer this single automated pipeline connecting cell and nuclei prep to Tapestri's microfluidics-based workflow." John Bashkin, Chief Strategy Officer of S2 Genomics.

Read More

Access Biologicals Completes the First-ever Commercially Available COVID-19 Seroconversion Panel to Confirm SARS-CoV-2 Antibody Assays

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without the independent data to help assess their analytical performance and enable comparisons between different testing methods. With Access Biologicals' seroconversion panel, diagnostic manufacturers, clinical laboratories and researchers will have a reliable benchmark against which they can develop, validate and troubleshoot other COVID-19 serological assays and testing. "An effective, sensitive and specific way to identify and confirm the SARS-CoV-2 infection is urgently needed," said Mike Crowley, Managing Director Access Biologicals. "Our COVID-19 seroconversion panel will help serological assays bridge the gap through precise validation, establishing sensitivity and helping determine the pre-seroconversion window period, which is the time after infection and before seroconversion, when antibodies appear." Collected in a longitudinal series, the Access Biologicals COVID-19 seroconversion panel consists of 14 members (units) of a unique human plasma sample drawn from a single donor during a developing SARS-CoV-2 infection. The panel illustrates the onset and decline of IgM, IgG and Ig total SARS-CoV-2 virus antibody titers over a period of 87 days.

Read More